Diastolic Heart Failure Mechanisms and Assessment Revisited
Source : https://pubmed.ncbi.nlm.nih.gov/38892754/
The syndrome of heart failure (HF) with preserved ejection fraction (HFpEF) makes up about half of the HF population. The HF mechanisms in these patients are varied and not fully...
Understand and address heart failure with preserved ejection fraction (HFpEF), highlighting its complex mechanisms and the urgency for early recognition and treatment to mitigate its progression and impact, particularly given its increasing prevalence in an aging population.
Full decongestion in acute heart failure therapy
Source : https://pubmed.ncbi.nlm.nih.gov/38880301/
Incomplete decongestion is the main cause of readmission in the early post-discharge period of a hospitalization for acute heart failure. Recent heart failure guidelines have highlighted initiation and rapid up-titration...
Achieving complete decongestion remains the primary therapeutic objective during hospitalization for heart failure, with early initiation and titration of quadruple therapy recommended to prevent readmissions for heart failure with reduced ejection fraction.
The Role of Inflammasomes in Heart Failure
Source : https://pubmed.ncbi.nlm.nih.gov/38791409/
Heart failure (HF) poses a significant world health challenge due to the increase in the aging population and advancements in cardiac care. In the pathophysiology of HF, the inflammasome has...
Understanding the role of inflammasomes in heart failure (HF) pathophysiology reveals their potential as biomarkers and therapeutic targets. Modulating inflammasome signaling could offer innovative strategies for managing HF.
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial
Source : https://pubmed.ncbi.nlm.nih.gov/38581389/
URL: https://www.clinicaltrials.gov; Unique identifier: NCT04509674.
Empagliflozin reduced the risk of HF in patients with left ventricular dysfunction or congestion after acute myocardial infarction.
2024 update in heart failure
Source : https://pubmed.ncbi.nlm.nih.gov/38806171/
In the last years, major progress has occurred in heart failure (HF) management. The 2023 ESC focused update of the 2021 HF guidelines introduced new key recommendations based on the...
Recent updates in heart failure management highlight significant advances such as the use of SGLT2 inhibitors and finerenone for prevention in diabetic CKD, and expanded treatments across HF spectrums. Emerging therapies like vericiguat and semaglutide show promise, while ongoing research continues to refine treatment strategies.